Meet us at

The session will be will be a mixture of presentations and panel discussions. The panel has an interesting mix of people from across all professions involved in commercialisation - consulting, tech transfer, UK public sector, industry and legal.

We hope this will be a lively, interactive session and look forward to seeing you there – Wed May 5, 8-9am (location room S404A - S404BC).

IP Pragmatics and InterAct will also be attending the annual BIO conference in Chicago in May 2009.

Marinova Pty Ltd has established a supply chain and developed a proprietary solvent-free process for extracting the active ingredient; fucoidan from organic brown seaweed. Fucoidan is a bioactive polysaccharide widely used in nutritional and cosmetic formulations primarily in Asia. To date, clinical studies have been performed on Marinova's premium extracts and have demonstrated functional food, skincare and pharmaceutical applications.

1. On both the "View NRPH costs as a PDF" and "View NRPH costs as Excel Document", there is now the ability to add in EPO validation costs to these reports.
2. If you choose to export the whole report to either pdf or Excel at this stage of the Financial Forecaster, ("View as a PDF" & "View as an Excel document") there is now the ability to choose whether to add in annuity (renewals) costs for these reports, and also to select the number of renewal years to be shown on the reports.

Dr Nicky Pattrick joins from GSK's business development department. Nicky has a experience of negotiating a wide range of collaborative and licensing agreements with both commercial and academic partners worldwide. Her areas of expertise are drug delivery, imaging and nanotechnology in the life sciences field. She holds a biochemistry degree from University College London and a PhD in drug delivery from the London School of Pharmacy.

Joining from Pfizer's Worldwide Business Development group Dr Deirdre O'Brien brings experience of in-licensing antiviral, antibacterial, antifungal and vaccines for human health indications. In addition to her business development expertise Deirdre has also gained significant experience in Pharmaceutical Sciences R&D in a variety of areas including crystallisation technologies, Inhalation drug delivery and materials assessment. She holds a PhD in Chemistry from University College Dublin, and is currently completing an MBA.

Elaine Eggington and Dr Quinton Fivelman expand IP Pragmatics expertise in commercialising early-stage technologies. Elaine has over 9 years experience in commercialising early stage life science products and technologies. She was Investment Manager with day to day responsibility for the Lachesis Fund, the £8m University Challenge Fund for the East Midlands, managing a portfolio of 30 start up companies and development technologies. Elaine has an MA from the University of Cambridge and an MSc from The City University.

Prior to joining IP Pragmatics Quinton managed business development and knowledge transfer at the London School of Hygiene and Tropical Medicine (University of London) where he was responsible for managing proof of concept funding for a range of public health technologies and launching new business initiatives by assisting many projects to move from the laboratory to the marketplace. He has a PhD in malaria molecular genetics and drug combinations from the London School of Hygiene and Tropical Medicine and an Honours degree in Pharmacology, Chemistry and Microbiology from the University of Cape Town, South Africa.

Rupert Osborn, IP Pragmatics CEO said: "I am very pleased to welcome Nicky, Deirdre, Elaine and Quinton to the team. Between them their breadth of "hands on" experience in the biotech, pharma and investment arena further enhances IP Pragmatics capability to deliver a unique combination scientific and business expertise to our clients."